{"id":"immunoscintigraphy-with-radiolabeled-cimzia","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (minimal from diagnostic dose)"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL386768","moleculeType":"Protein","molecularWeight":"1507.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cimzia is a TNF-α inhibitor monoclonal antibody that, when radiolabeled, allows scintigraphic imaging of TNF-α-producing cells at sites of inflammation. This diagnostic approach enables non-invasive visualization of disease activity and localization in inflammatory conditions. The radiolabel allows detection via nuclear imaging while the antibody provides specific targeting to TNF-α-expressing immune cells.","oneSentence":"Radiolabeled Cimzia (certolizumab pegol) is used as an imaging agent to visualize and localize TNF-α-expressing immune cells in inflammatory disease sites.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:43.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of TNF-α-expressing immune cells in inflammatory diseases (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT01590966","phase":"PHASE3","title":"Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-10-18","conditions":"Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Immunoscintigraphy with radiolabeled Cimzia®.","genericName":"Immunoscintigraphy with radiolabeled Cimzia®.","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Radiolabeled Cimzia (certolizumab pegol) is used as an imaging agent to visualize and localize TNF-α-expressing immune cells in inflammatory disease sites. Used for Imaging of TNF-α-expressing immune cells in inflammatory diseases (Phase 3 investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}